What Is a Delta in THC? Delta-8, Delta-9, and Delta-10

“Delta” in THC refers to the position of a specific chemical bond in the molecule. Every THC variant shares the same basic skeleton of atoms, but a single double bond between two carbon atoms can sit at different spots along the ring structure, and that spot gets a number. Delta-9-THC has the bond at the ninth carbon position, delta-8 at the eighth, and delta-10 at the tenth. That one-position shift sounds trivial, but it changes the shape of the molecule enough to alter how it fits into your brain’s receptors, which is why these compounds produce noticeably different effects.

The Double Bond and Why Its Position Matters

THC molecules are built on a structure that chemists call a terpenoid. Picture a set of connected rings made of carbon atoms with various side chains hanging off them. Along one of those rings, two adjacent carbon atoms share a double bond instead of the usual single bond. That double bond creates a slight kink in the molecule’s overall shape, and the location of that kink determines which version of THC you’re dealing with. In delta-9-THC, the double bond sits between carbon atoms 9 and 10. Slide it one position to carbons 8 and 9, and you get delta-8-THC. Move it to carbons 10 and 10a, and you get delta-10-THC.

This matters because your body’s cannabinoid receptors are shaped like locks, and the THC molecule has to fit into them at a precise angle. Even a slight change in molecular geometry alters how snugly the molecule binds and how strongly it activates the receptor. Delta-9-THC fits well and activates the CB1 receptor as a partial agonist, producing the full spectrum of effects people associate with cannabis: euphoria, altered perception, increased appetite, and so on.¹ Delta-8 and delta-10 THC bind to the same receptor but with lower affinity, and the downstream consequences of that weaker binding can be substantial.

Delta-9-THC Is the One You Already Know

When someone says “THC” without a number, they mean delta-9-THC. It’s the most abundant psychoactive compound in the cannabis plant and the one responsible for the classic marijuana high. It was first isolated and synthesized in the 1960s, and decades of research have mapped out its pharmacology in detail. Delta-9-THC acts as a partial agonist at the CB1 cannabinoid receptor, and the intensity of its effects depends on factors like how many CB1 receptors a given tissue expresses and what the body’s own endocannabinoid system is already doing at the time.¹

Delta-9-THC is also the compound that regulators track. In the United States, the legal distinction between “hemp” and “marijuana” hinges entirely on delta-9-THC concentration: plants with 0.3% or less delta-9-THC by dry weight are classified as hemp, while anything above that threshold remains a Schedule I controlled substance.² That narrow definition is what opened the door for the other deltas.

Delta-8-THC and Why It Became So Popular

Delta-8-THC was first isolated from a cannabis plant grown in Maryland back in 1966, but it exists in the plant at vanishingly low concentrations.³ For decades it was little more than a footnote in cannabinoid research. That changed after the 2018 Farm Bill legalized hemp and hemp-derived products, as long as they stayed below the 0.3% delta-9-THC threshold. Because that law specifically named delta-9, manufacturers realized they could convert CBD extracted from legal hemp into delta-8-THC using acid-catalyzed chemical reactions, then sell the resulting product without running afoul of the federal definition of marijuana.²

Functionally, delta-8-THC is close to delta-9: it’s chemically similar, it binds to the same CB1 receptor, and it produces psychoactive effects.⁴ But its binding affinity is weaker, which translates to a milder high at equivalent doses. In a controlled crossover trial comparing the two compounds head-to-head, 20 mg of delta-8-THC produced significantly less impairment, lower negative subjective effects, and smaller increases in heart rate than 20 mg of delta-9-THC. Doubling the delta-8 dose to 40 mg, however, brought those measures roughly in line with 20 mg of delta-9. Both doses of delta-8 produced similar “drug liking” ratings to delta-9, suggesting that the appeal and potential for misuse are comparable once you adjust the dose upward.⁵

That milder-per-milligram profile is a big part of delta-8’s marketing pitch. Surveys of delta-8 consumers found that about half reported using it for health conditions, most commonly anxiety, stress, depression, and chronic pain. Respondents compared it favorably to both delta-9-THC and pharmaceutical medications and reported often substituting delta-8 for those alternatives.⁶

Delta-10-THC Is Quite Different from the Other Two

Delta-10-THC gets lumped in with delta-8 in marketing, often positioned as an “energizing” or “sativa-like” alternative. The research tells a different story. In receptor-binding lab studies, both the trans and cis forms of delta-10-THC showed strong affinity for the CB1 receptor in a radioligand test but failed to show any agonist activity at concentrations up to 10 micromolar, suggesting a lack of THC-like psychoactivity.⁷ In other words, delta-10-THC can occupy the receptor but doesn’t flip the switch the same way delta-8 or delta-9 does. Some researchers have suggested that certain delta-10 isomers may even act as antagonists at CB1, effectively blocking the receptor rather than activating it.⁸

This is worth pausing on, because many delta-10 products are sold with the clear implication that they’ll get you high. If the compound itself isn’t meaningfully psychoactive, any buzz from a delta-10 product may come from delta-8 or delta-9 impurities mixed in during manufacturing rather than from the delta-10 itself. The science here is still early, and most of what’s known about delta-10 is inferred from its structural similarity to the better-studied isomers.⁸

How Delta-8 and Delta-10 Are Actually Made

Neither delta-8 nor delta-10 is typically extracted from the cannabis plant, because neither occurs in meaningful quantities naturally. Instead, manufacturers start with CBD isolated from hemp and use acid-catalyzed chemical reactions to rearrange the molecule’s structure. Under acidic conditions, CBD can be converted into various THC isomers, including delta-9, delta-8, and delta-10, along with a long list of other cannabinoids and side products.⁹

The problem is that these reactions are messy. Under poorly controlled or harsh conditions, the acid catalysis yields not just the target cannabinoid but numerous unintended byproducts.¹⁰ Because most of this manufacturing happens outside regulated laboratory environments, the quality of the starting CBD and the precision of the chemistry vary enormously from one producer to the next.

The Contaminant Problem

Researchers who analyzed commercially available delta-8-THC products found a range of impurities. These included leftovers from low-quality CBD feedstock, known side-reaction products from the conversion chemistry, and several compounds whose origins couldn’t be identified at all. One unidentified contaminant appeared to contain an amine group, a type of chemical not used in any published method for making delta-8 from CBD. Another appeared to contain a hexose sugar whose source was unknown.¹¹ A broader review of delta-8 chemistry noted that synthetically produced delta-8-THC is expected to contain residual starting materials, leftover reagents, and reaction side products.³

This isn’t just an abstract chemistry concern. Without standardized manufacturing practices or mandatory third-party testing, consumers have no way of knowing what else is in the product beyond the THC isomer on the label. The difference between a cleanly synthesized cannabinoid and one produced in a sloppy garage operation looks the same in the packaging.

Poison Center Data and Safety Signals

The surge in delta-8 availability has been accompanied by a sharp increase in calls to poison centers. Between 2021 and 2022, nearly 5,000 exposures involving delta-8-THC as the primary substance were reported to U.S. poison centers, with the rate per 100,000 population climbing by about 79% from one year to the next. Most cases resulted in minor or moderate effects, but roughly 3% were classified as major.¹²

A separate analysis of over 5,000 cases reported during the same period found that children under six accounted for roughly 30% of exposures, with the most common age being just two years old. Ingestion was the route of exposure in the vast majority of cases, and more than a third of all cases experienced a serious medical outcome. About 5% of those reported required admission to a critical care unit.¹³ The child exposure numbers reflect a practical reality of the delta-8 market: many products are sold as gummies, chocolates, and other edibles that look identical to ordinary candy.

Drug Testing Cannot Tell the Deltas Apart

If you use any THC isomer and then take a standard urine drug test, you will almost certainly test positive. The immunoassay-based screens used in workplace and clinical testing were designed to detect delta-9-THC metabolites, but they cross-react extensively with delta-8 and delta-10 metabolites. In laboratory testing of six commercially available immunoassay kits, all six cross-reacted with delta-8-THC metabolites. Five of the six also cross-reacted with delta-10-THC analogs.¹⁴

Even more advanced confirmatory testing can run into trouble. Routine urine testing in Sweden that targeted delta-9-THC’s main metabolite flagged an unknown interfering peak that had nearly the same mass and fragmentation pattern as the expected compound but a slightly different retention time, preventing a straightforward positive identification.¹⁵ The takeaway is straightforward: using delta-8 or delta-10 products and expecting to pass a drug test is not a realistic plan, despite some marketing claims to the contrary.

An Old Antiemetic Study That Keeps Coming Up

One of the most frequently cited pieces of delta-8 research is a small study from the mid-1990s that administered delta-8-THC to eight children undergoing cancer chemotherapy. The children received the compound orally before each round of treatment, and over a total of 480 administrations, vomiting was completely prevented. Side effects were described as negligible, limited to some irritability and mild euphoria in two of the eight patients, with no anxiety or hallucinations.¹⁶ The study’s authors described delta-8-THC as having lower psychotropic potency than delta-9-THC, which was part of the rationale for testing it in children.

This study gets cited endlessly in delta-8 marketing materials, but it’s worth noting its limitations. Eight patients is a very small sample. The study had no placebo arm. And it was published nearly 30 years ago with no substantial follow-up trials. It’s an interesting piece of evidence, but it carries nowhere near enough weight to support broad therapeutic claims.

Relatives Beyond Delta-8, -9, and -10

The three “delta” compounds in the title are far from the only THC variants that exist. The acid-catalyzed conversion of CBD can produce delta-7-THC, delta-11-THC, and various alkylated and hydroxylated analogs.⁹ Meanwhile, the unregulated cannabinoid market has introduced products containing hexahydrocannabinol (HHC), tetrahydrocannabiphorol (THCP), and other compounds with longer side chains or fully saturated ring structures. Research on CB1 receptor activation found that several of these newer compounds, including THCP and HHCP, showed higher potential for activating CB1 than delta-9-THC itself, based on either greater efficacy or greater potency.¹⁷

That finding matters because these compounds are already showing up in consumer products, often with minimal labeling and no dosing guidance. A substance that is more potent at CB1 than delta-9-THC is not something to experiment with casually, yet these products are sold alongside delta-8 gummies at gas stations and vape shops with no regulatory distinction.

Why the Plant Makes THC in the First Place

Cannabis produces cannabinoids in tiny, mushroom-shaped structures called glandular trichomes that cover the plant’s leaves and flowers, with the highest density on female flowers. The trichomes store cannabinoids in a balloon-like cavity, and when the trichome ruptures from heat or physical damage, its sticky contents coat the plant surface. That viscous layer glues the mouthparts and legs of insect herbivores, discouraging further feeding. Cannabinoid production also increases with heat stress, UV-B radiation, low soil moisture, and poor mineral nutrition, suggesting the compounds serve multiple protective roles for the plant, from herbivore defense to a kind of biological sunscreen.¹⁸

Roots, by contrast, have no glandular trichomes and accumulate no cannabinoids. The entire THC production apparatus is an above-ground phenomenon linked to the plant’s environmental stresses. The specific isomer of THC that ends up in the trichome depends on the enzymes the plant expresses; delta-9-THC dominates because the plant’s biosynthetic enzyme preferentially produces its precursor acid form. The trace amounts of delta-8 found naturally in aged cannabis are thought to result from slow, non-enzymatic degradation of delta-9-THC over time, not from a dedicated biosynthetic pathway.

State-Level Regulation Is a Patchwork

Federal law’s narrow focus on delta-9-THC created the loophole that launched the delta-8 industry. The 2018 Farm Bill removed hemp from the Controlled Substances Act, allowing legal cultivation and extraction as long as the delta-9-THC concentration stayed at or below 0.3% by dry weight.² Because the law didn’t mention delta-8 or delta-10, manufacturers argued their hemp-derived products were federally legal. Many states have since passed their own restrictions. Some have banned delta-8 outright, others regulate it under existing cannabis programs, and still others have taken no action. The legal landscape shifts frequently enough that a product legally purchased in one state can be contraband an hour’s drive away.

Poison center data reflect this regulatory patchwork. Nearly 70% of delta-8-THC exposure reports came from the U.S. South, a region where delta-8 availability was widespread and state-level restrictions were relatively rare during the study period.¹² Whether you can buy these products legally depends on where you live, but whether they’ll show up on a drug test does not.